{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:49:07Z","timestamp":1792000147529,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-020-00802-x","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T06:02:46Z","timestamp":1602050566000},"page":"1439-1448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":189,"title":["Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters"],"prefix":"10.1038","volume":"5","author":[{"given":"Shuofeng","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-5659","authenticated-orcid":false,"given":"Runming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper Fuk-Woo","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Jinxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-6228","authenticated-orcid":false,"given":"Tianfan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenn Ka-Heng","family":"Chik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Chak-Yiu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5340-9710","authenticated-orcid":false,"given":"Lijian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-3530","authenticated-orcid":false,"given":"Dong-Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-1552","authenticated-orcid":false,"given":"Kwok-Yung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-6899","authenticated-orcid":false,"given":"Hongzhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"802_CR1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"802_CR2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF-W Chan","year":"2020","unstructured":"Chan, J. F.-W. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514\u2013523 (2020).","journal-title":"Lancet"},{"key":"802_CR3","unstructured":"WHO Coronavirus Disease (COVID-19) Situation Report, 157 (World Health Organization, 2002)."},{"key":"802_CR4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrmicro775","volume":"1","author":"K Stadler","year":"2003","unstructured":"Stadler, K. et al. SARS\u2014beginning to understand a new virus. Nat. Rev. Microbiol. 1, 209\u2013218 (2003).","journal-title":"Nat. Rev. Microbiol."},{"key":"802_CR5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","volume":"28","author":"JFW Chan","year":"2015","unstructured":"Chan, J. F. W. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465\u2013522 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"802_CR6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"802_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"802_CR8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"802_CR9","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","journal-title":"Sci. Transl. Med."},{"key":"802_CR10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C. & Yuen, K.-Y. Coronaviruses\u2014drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15, 327\u2013347 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"802_CR11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","journal-title":"Science"},{"key":"802_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from COVID-19 virus and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"802_CR13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779\u2013782 (2020).","journal-title":"Science"},{"key":"802_CR14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323, 1824\u20131836 (2020).","journal-title":"JAMA"},{"key":"802_CR15","doi-asserted-by":"crossref","first-page":"105969","DOI":"10.1016\/j.ijantimicag.2020.105969","volume":"55","author":"MB Serafin","year":"2020","unstructured":"Serafin, M. B. et al. Drug repositioning an alternative for the treatment of coronavirus COVID-19. Int. J. Antimicrob. Agents 55, 105969 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"802_CR16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","volume":"585","author":"VJ Munster","year":"2020","unstructured":"Munster, V. J. et al. Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268\u2013272 (2020).","journal-title":"Nature"},{"key":"802_CR17","unstructured":"NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. National Institutes of Health https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 (2020)."},{"key":"802_CR18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569\u20131578 (2020).","journal-title":"Lancet"},{"key":"802_CR19","doi-asserted-by":"publisher","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2021436 (2020).","DOI":"10.1056\/NEJMoa2021436"},{"key":"802_CR20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IF-N Hung","year":"2020","unstructured":"Hung, I. F.-N. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695\u20131704 (2020).","journal-title":"Lancet"},{"key":"802_CR21","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1002\/anie.200701021","volume":"46","author":"N Yang","year":"2007","unstructured":"Yang, N. et al. Bismuth complexes inhibit the SARS coronavirus. Angew. Chem. Int. Ed. 46, 6464\u20136468 (2007).","journal-title":"Angew. Chem. Int. Ed."},{"key":"802_CR22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/(SICI)1099-1557(199611)5:6<399::AID-PDS243>3.0.CO;2-4","volume":"5","author":"GA Pipkin","year":"1996","unstructured":"Pipkin, G. A., Mills, J. G., Kler, L., Dixon, J. S. & Wood, J. R. The safety of ranitidine bismuth citrate in controlled clinical studies. Pharmacoepidem. Drug Safe. 5, 399\u2013407 (1996).","journal-title":"Pharmacoepidem. Drug Safe."},{"key":"802_CR23","doi-asserted-by":"publisher","unstructured":"Sadler, P. J. & Sun, H. Ranitidine bismuth(iii) citrate. J. Chem. Soc. Dalton Trans. https:\/\/doi.org\/10.1039\/DT9950001395 (1995).","DOI":"10.1039\/DT9950001395"},{"key":"802_CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2125.1996.03929.x","volume":"42","author":"KM Koch","year":"1996","unstructured":"Koch, K. M., Davis, I. M., Gooding, A. E. & Yin, Y. Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate. Br. J. Clin. Pharmacol. 42, 201\u2013205 (1996).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"802_CR25","doi-asserted-by":"publisher","unstructured":"Chan, J. F.-W. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa325 (2020).","DOI":"10.1093\/cid\/ciaa325"},{"key":"802_CR26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271 (2020).","journal-title":"Cell Res."},{"key":"802_CR27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay, M. Z., Poh, C. M., R\u00e9nia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363\u2013374 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"802_CR28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"802_CR29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1039\/c9mt00085b","volume":"11","author":"T Cheng","year":"2019","unstructured":"Cheng, T. et al. Bismuth drugs tackle Porphyromonas gingivalis and attune cytokine response in human cells. Metallomics 11, 1207\u20131218 (2019).","journal-title":"Metallomics"},{"key":"802_CR30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41467-018-02828-6","volume":"9","author":"R Wang","year":"2018","unstructured":"Wang, R. et al. Bismuth antimicrobial drugs serve as broad-spectrum metallo-\u03b2-lactamase inhibitors. Nat. Commun. 9, 439 (2018).","journal-title":"Nat. Commun."},{"key":"802_CR31","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1073\/pnas.0913970107","volume":"107","author":"SJ Cun","year":"2010","unstructured":"Cun, S. J. & Sun, H. A zinc-binding site by negative selection induces metallodrug susceptibility in an essential chaperonin. Proc. Natl Acad. Sci. USA 107, 4943\u20134948 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"802_CR32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"YM Baez-Santos","year":"2015","unstructured":"Baez-Santos, Y. M., St John, S. E. & Mesecar, A. D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21\u201338 (2015).","journal-title":"Antiviral Res."},{"key":"802_CR33","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1093\/nar\/gkz409","volume":"47","author":"ZH Jia","year":"2019","unstructured":"Jia, Z. H. et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. Nucleic Acids Res. 47, 6538\u20136550 (2019).","journal-title":"Nucleic Acids Res."},{"key":"802_CR34","doi-asserted-by":"crossref","first-page":"18265","DOI":"10.1074\/jbc.R600008200","volume":"281","author":"SS Patel","year":"2006","unstructured":"Patel, S. S. & Donmez, I. Mechanisms of helicases. J. Biol. Chem. 281, 18265\u201318268 (2006).","journal-title":"J. Biol. Chem."},{"key":"802_CR35","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bcp.2012.08.012","volume":"84","author":"Y-S Keum","year":"2012","unstructured":"Keum, Y.-S. & Jeong, Y.-J. Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target. Biochem. Pharmacol. 84, 1351\u20131358 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"802_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0959-440X(02)00298-1","volume":"12","author":"JM Caruthers","year":"2002","unstructured":"Caruthers, J. M. & McKay, D. B. Helicase structure and mechanism. Curr. Opin. Struct. Biol. 12, 123\u2013133 (2002).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"802_CR37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpha.2020.04.008","volume":"10","author":"MU Mirza","year":"2020","unstructured":"Mirza, M. U. & Froeyen, M. Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J. Pharm. Anal. 10, 320\u2013328 (2020).","journal-title":"J. Pharm. Anal."},{"key":"802_CR38","doi-asserted-by":"crossref","first-page":"39578","DOI":"10.1074\/jbc.C300328200","volume":"278","author":"JA Tanner","year":"2003","unstructured":"Tanner, J. A. et al. The severe acute respiratory syndrome (SARS) coronavirus NTPase\/helicase belongs to a distinct class of 5\u2032 to 3\u2032 viral helicases. J. Biol. Chem. 278, 39578\u201339582 (2003).","journal-title":"J. Biol. Chem."},{"key":"802_CR39","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00957-12","volume":"56","author":"AO Adedeji","year":"2012","unstructured":"Adedeji, A. O. et al. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob. Agents Chemother. 56, 4718\u20134728 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"802_CR40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/gut.41.2.181","volume":"41","author":"KD Bardhan","year":"1997","unstructured":"Bardhan, K. D., Dallaire, C., Eisold, H. & Duggan, A. E. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Gut 41, 181\u2013186 (1997).","journal-title":"Gut"},{"key":"802_CR41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gutjnl-2020-321013","volume":"69","author":"L Lin","year":"2020","unstructured":"Lin, L. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69, 997\u20131001 (2020).","journal-title":"Gut"},{"key":"802_CR42","unstructured":"Roberts, M. et al. Covid-19: a complex multisystem clinical syndrome. The BMJ Opinion https:\/\/blogs.bmj.com\/bmj\/2020\/05\/01\/covid-19-a-complex-multisystem-clinical-syndrome\/ (2020)."},{"key":"802_CR43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cbpa.2012.01.006","volume":"16","author":"H Li","year":"2012","unstructured":"Li, H. & Sun, H. Recent advances in bioinorganic chemistry of bismuth. Curr. Opin. Chem. Biol. 16, 74\u201383 (2012).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"802_CR44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"802_CR45","doi-asserted-by":"crossref","first-page":"101054","DOI":"10.1016\/j.isci.2020.101054","volume":"23","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Bismuth porphyrin antagonizes cisplatin-induced nephrotoxicity via unexpected metallothionein-independent mechanisms. iScience 23, 101054 (2020).","journal-title":"iScience"},{"key":"802_CR46","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","volume":"1","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility and laboratory studies of COVID-19: an observational study. Lancet Microbe 1, e14\u2013e23 (2020).","journal-title":"Lancet Microbe"},{"key":"802_CR47","volume":"10","author":"S Yuan","year":"2019","unstructured":"Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat. Commun. 10, 120 (2019).","journal-title":"Nat. Commun."},{"key":"802_CR48","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/jac\/dkw194","volume":"71","author":"S Yuan","year":"2016","unstructured":"Yuan, S. et al. A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication. J. Antimicrob. Chem. 71, 2489\u20132497 (2016).","journal-title":"J. Antimicrob. Chem."},{"key":"802_CR49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.10.007","volume":"160","author":"JF-W Chan","year":"2018","unstructured":"Chan, J. F.-W. et al. The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K\/Akt pathway and protects Zika virus-infected A129 mice: a host-targeting treatment strategy. Antiviral Res. 160, 38\u201347 (2018).","journal-title":"Antiviral Res."},{"key":"802_CR50","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1128\/AAC.00306-15","volume":"59","author":"S Yuan","year":"2015","unstructured":"Yuan, S. et al. Cross-protection of influenza A virus infection by a DNA aptamer targeting the PA endonuclease domain. Antimicrob. Agents Chemother. 59, 4082\u20134093 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"802_CR51","first-page":"e00310","volume":"58","author":"JF-W Chan","year":"2020","unstructured":"Chan, J. F.-W. et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp\/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J. Clin. Microb. 58, e00310\u2013e00320 (2020).","journal-title":"J. Clin. Microb."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00802-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T22:59:10Z","timestamp":1670281150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1038\/s41564-020-00802-x","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.S., K.-Y.Y., S.Y., R.W., H.L., J.F.-W.C., T.C. and S.W. have a pending patent application related to this manuscript. J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}